Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | STAT6 | P42226 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14146863 | 0.89 | SYK (0.56) | SYKMAPK9MAPK10MAPK8STAT6 | |
| SCHEMBL3502715 | 0.86 | SYK (0.54) | SYKMAPK9MAPK10MAPK8STAT6 | |
| SCHEMBL13363164 | 0.81 | EPHB4 (0.50) | SYKMAPK9MAPK10MAPK8STAT6 | |
| SCHEMBL1866937 | 0.81 | MAPT (0.60) | SYKMAPK10STAT6 | |
| SCHEMBL3504716 | 0.75 | CSF1R (0.43) | SYK | |
| SCHEMBL1865052 | 0.75 | BRAF (0.50) | SYKMAPK10MAPK8 | |
| SCHEMBL735531 | 0.72 | SYK (1.00) | SYK | |
| SCHEMBL1475718 | 0.72 | SYK (0.48) | SYKMAPK9MAPK10MAPK8 | |
| SCHEMBL16466605 | 0.72 | SYK (0.82) | SYKMAPK9MAPK10 | |
| SCHEMBL1632767 | 0.72 | JAK2 (0.54) | SYKMAPK9MAPK10MAPK8STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | claimed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SYK 4095/4885MAPK9 185/4885MAPK10 338/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | SYK 4070/4885MAPK9 232/4885MAPK10 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.